Capecitabine, developed by F. Hoffmann-La Roche Ltd, entered the markets in the US, Canada and Sweden in 1998 under the trade name of Xeloda and then spread through over 80 countries and regions in 2 years. In Mar. 2001, capecitabine entered China to be clinically used for the treatment of advanced breast cancer, colorectal cancer and other solid tumors. The chemotherapy for colorectal cancer has mainly relied on traditional cytotoxic drugs for years. Capecitabine, as orally-administered tablets, acts directly in intestine and drug concentration in the tumor tissues is higher than that in blood. Besides, it features flexible dose adjustments and compliant method of administration. All this has contributed to its market growth.
Capecitabine develops fast after entering China, annual sales value rising from less than CNY 100 million in 2005 to CNY 635 million in 2014 and CAGR reaching up to 25.3% during this period. Capecitabine enjoys a vast demand in China. Currently, there are mainly five manufacturers of capecitabine in China: Shanghai Roche Pharmaceutical Co., Ltd, Qilu Pharmaceutical Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, among which Shanghai Roche Pharmaceutical Co., Ltd has the largest market share of over 95% with sales value exceeding CNY 600 million in 2014.
With the degradation of environment and lifestyle changes brought about by improved living standards, the incidence of cancer keeps increasing in China. Therefore, capecitabine has good prospects in China and its market size will keep growing.
Readers can get at least the following information from this report:
-market share of manufacturers of capecitabine in China
-price of capecitabine in Chinese market
-major manufacturers of capecitabine in Chinese market
-share of dosage forms of capecitabine in China
-market outlook of capecitabine in China
The author suggests the following groups of people purchase this report:
-manufacturers of antitumor drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service